Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. II. Optimization of the phenylpiperazine moiety of 1-[5-Methyl-1-(2- pyrimidinyl)-4-pyrazolyl]-3-phenylpiperazinyl-1-trans-propenes

Chemical and Pharmaceutical Bulletin

Volumn 50, Issue 4, 2002, Pages 453-462

  Naito, Hiroyuki ^a   Ohsuki, Satoru ^a   Sugimori, Masamichi ^a   Atsumi, Ryo ^a   Minami, Megumi ^a   Nakamura, Yoshihide ^b   Ishii, Mineko ^a   Hirotani, Kenji ^a   Kumazawa, Eiji ^a   Ejima, Akio ^a  

^a DAIICHI SANKYO CO   (Japan)

^b FUJI CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

Antitumor activity; Cytotoxic activity; Pyrazole; Structure activity relationship

Indexed keywords

3 [4 (3 ACETYLAMINO) 1 PIPERAZINYL] 1 [5 METHYL 1 (2 PYRIMIDINYL) 4 1H PYRAZOLYL] 1 PROPENE; 3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 1 [5 METHYL 1 (2 PYRIMIDINYL) 4 PYRAZOLYL] 1 PROPENE; 3 [4 (3 HYDROXYPHENYL) 1 PIPERAZIN] 1 [5 METHYL 1 (2 PYRIMIDINYL) 4 1H PYRAZOLYL] 1 PROPENE; 3 [4 (3,5 DICHLOROPHENYL) 1 PIPERIDINYL] 1 [5 METHYL 1 (2 PYRIMIDINYL) 4 1H PYRAZOLYL] 1 PROPENE; 3 [4 (3,5 DIFLUOROPHENYL) 1 PIPERAZINYL] 1 [5 METHYL 1 (2 PYRIMIDINYL) 4 1H PYRAZOLYL] 1 PROPENE; 3 [4 (3,5 DIFLUOROPHENYL) 3 METHYL 1 PIPERAZINYL] 1 [5 METHYL 1 (2 PYRIMIDINYL) 4 1H PYRAZOLYL] 1 PROPENE; 3 [4 (3,5 DIFLUOROPHENYL) 3 OXO 1 PIPERAZINYL] 1 [5 METHYL 1 (2 PYRIMIDINYL) 4 1H PYRAZOLYL] 1 PROPENE; DOXORUBICIN; FLUOROURACIL; PHENYLPIPERAZINE; PIPERAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINYLPYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE; 3 (4 (3,5 DICHLOROPHENYL) 1 PIPERAZINYL) 1 (5 METHYL 1 (2 PYRIMIDINYL) 4 1H PYRAZOLYL) 1 TRANS PROPEN; 3 (4 (3,5 DIFLUOROPHENYL) 1 PIPERAZINYL) 1 (5 METHYL 1 (2 PYRIMIDINYL) 4 1H PYRAZOLYL) 1 TRANS PROPEN HYDROCHLORIDE; 3-(4-(3,5-DICHLOROPHENYL)-1-PIPERAZINYL)-1-(5-METHYL-1-(2-PYRIMIDINYL)-4-1H-PYRAZOLYL)-1-TRANS-PROPEN; 3-(4-(3,5-DIFLUOROPHENYL)-1-PIPERAZINYL)-1-(5-METHYL-1-(2-PYRIMIDINYL)-4-1H-PYRAZOLYL)-1-TRANS-PROPEN HYDROCHLORIDE; ANTINEOPLASTIC AGENT; DZ 3358; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY TEMPERATURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MURINE LEUKEMIA; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; TUMOR GROWTH; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; FIBROSARCOMA; LEUKEMIA P 388; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MOUSE STRAIN; MULTIDRUG RESISTANCE; PATHOLOGY; SARCOMA; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FIBROSARCOMA; HUMANS; LEUKEMIA P388; LUNG NEOPLASMS; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; PYRAZOLES; PYRIMIDINES; SARCOMA, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 0011723947     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.50.453     Document Type: Article

References (12)

1. Naito H., Sugimori M., Mitsui I., Nakamura Y., Ishii M., Iwahana M., Hirotani K., Kumazawa E., Ejima A., Chem. Pharm. Bull., 47, 1679-1684 (1999).
2. Compounds 4e, g, and h, were commercially available. The synthesis of 4f; Martin G. E., Elgin R. J., Jr., Mathiasen J. R., Davis C. B., Kesslick J. M., Baldy W. J., Shank R. P., DiStefano D. L., Fedde C. L., Scott M. K., J. Med. Chem., 32, 1052-1056 (1989)
3. 4i; Lopez-Rodriguez M. L., Morcillo M. J., Fernandez E., Rosado M. L., Orensanz L., Beneytez M. E., Manzanares J., Fuentes J. A., Schaper Klaus-Jurgen., Bioorg. Med. Chem. Lett., 9, 1679-1682 (1999).
4. Ueno K., Ohmura Y., Moroi R., Akashi A., Ger. Patent 2038503 [Chem. Abstr., 75, 49121c (1971)].
5. Mukaiyama T., Harada T., Chem. Lett., 1981, 1527-1528.
6. Zhao S.-H., Miller A. K., Berger J., Flippin L. A., Tetrahedron Lett., 37, 4463-4466 (1996).
7. Cortese N. A., Ziegler C. B., Hrnjez B. J., Heck R. F., J. Org. Chem., 43, 2952-2958 (1978).
8. Poindexter G. S., Owens D. A., Dolan P. L., Woo E., J. Org. Chem., 57, 6257-6265 (1992).
9. Barr W. H., Riegelman S., J. Pharm. Sci., 59, 154-163 (1970).
10. Ishii M., Iwahana M., Mitsui I., Minami M., Imagawa S., Tohgo A., Ejima A., Anticancer Drugs, 11, 353-362 (2000).
11. Iwahana M., Ochi Y., Ejima A., Anticancer Research, 20, 785-792 (2000).
12. Mitsui I., Kumazawa E., Aonuma M., Sugimori M., Ohsuki S., Uoto K., Ejima A., Terasawa H., Sato K., Jpn. J. Cancer Res., 86, 776-782 (1995).